“`html

Beta-blockers Linked to Increased ⁤Heart Risk in Women ⁢After Heart Attack

Women treated with ⁤beta-blockers (β-blockers) for post-myocardial infarction (MI) without reduced left ventricular ⁤ejection fraction (LVEF) have ⁤a 45% increased risk of⁢ MI, heart failure hospitalization, or death compared with men, according ‍to new study findings. The results, ⁤published in the European Heart Journal, suggest a ⁣need to re-evaluate β-blocker use in‍ post-MI women without reduced LVEF, with a view toward more sex-specific⁢ prescribing strategies.¹

“Despite ⁢the underlying reasons not being fully understood, it is indeed well⁢ established that women and men do not receive equal management-including pharmacological therapies-following an ACS [acute coronary syndrome],” the authors ‍discussed. “Moreover, even though ⁢findings vary ⁢across studies, several reports suggest that women may experience‍ worse long-term outcomes than men after⁣ ACS.”¹

Cardiovascular Disease in Women: A Growing Concern

Cardiovascular disease (CVD) affects nearly⁢ 60 million women in⁢ the ⁢United states alone, and only 44% see it as ⁤a significant health threat for women.This is⁤ largely in response to the prioritization of male enrollment in CVD clinical trials due to dissimilarities ⁢in⁣ women’s and men’s hormones, platelet reactivity, P2Y12 inhibitors,⁤ and the likelihood of developing comorbidities, which greatly impact responses ⁤to treatment.⁣ Continued evidence shows⁣ that women with cardiovascular conditions have increased adverse responses to cardiovascular drugs compared with men, with a risk that is 1.5 to 1.7 times higher. This underscores the critical⁢ need